| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 362.29K | 143.28K | 1.46M | 1.46M | 120K | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 35.32% | -0.6% | 9.18% | 0% | -0.92% | -1% | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 2.22M | 5.08M | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | 1.52% | 3.48% | - | - | - | - | - | - |
| Gross Profit | 362.29K | 143.28K | -761.5K | -3.62M | 120K | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | 1% | 1% | -0.52% | -2.48% | 1% | - | - | - | - | - |
| Gross Profit Growth % | 8.9% | -0.6% | -6.31% | -3.75% | 1.03% | -1% | - | - | - | - |
| Operating Expenses | 1.76M | 4.63M | 3.08M | 1.36M | 17.73M | 8.32M | 26.56M | 34.46M | 17.13M | 27.24M |
| OpEx % of Revenue | 4.85% | 32.32% | 2.11% | 0.93% | 147.76% | - | - | - | - | - |
| Selling, General & Admin | 89.15K | 272.39K | 3.07M | 1.28M | 3.87M | 4.1M | 12.36M | 9.96M | 10.03M | 11.44M |
| SG&A % of Revenue | 0.25% | 1.9% | 2.11% | 0.88% | 32.25% | - | - | - | - | - |
| Research & Development | 0 | 0 | 0 | 0 | 6.37M | 4.22M | 14.2M | 6.93M | 7.1M | 6.1M |
| R&D % of Revenue | - | - | - | - | 53.06% | - | - | - | - | - |
| Other Operating Expenses | 1.67M | 4.36M | 8.7K | 84.39K | 7.49M | 0 | 0 | 17.57M | 0 | 9.7M |
| Operating Income | -1.4M | -4.49M | -3.84M | -4.98M | -17.61M | -8.32M | -26.56M | -34.46M | -17.13M | -27.24M |
| Operating Margin % | -3.85% | -31.32% | -2.63% | -3.41% | -146.76% | - | - | - | - | - |
| Operating Income Growth % | -19.34% | -2.21% | 0.14% | -0.3% | -2.53% | 0.53% | -2.19% | -0.3% | 0.5% | -0.59% |
| EBITDA | -1.13M | -4.21M | -3.83M | -4.95M | -17.56M | -8.23M | -26.45M | -34.4M | -17.09M | -27.23M |
| EBITDA Margin % | -3.12% | -29.38% | -2.63% | -3.39% | -146.33% | - | - | - | - | - |
| EBITDA Growth % | -23.67% | -2.72% | 0.09% | -0.29% | -2.55% | 0.53% | -2.21% | -0.3% | 0.5% | -0.59% |
| D&A (Non-Cash Add-back) | 265.22K | 278.21K | 8.7K | 32.53K | 51K | 86K | 106K | 60K | 37K | 9K |
| EBIT | -1.4M | -4.49M | -3.84M | -4.93M | -15.66M | -6.1M | -25.88M | -17.36M | -11.32M | -24.24M |
| Net Interest Income | -39.4K | -43.7K | -2.42K | -233.24K | -3.31M | -320K | -640K | -193K | -476K | -120K |
| Interest Income | 0 | 0 | 0 | 0 | 7K | 0 | 0 | 30K | 22K | 533K |
| Interest Expense | 39.4K | 43.7K | 2.42K | 233.24K | 3.31M | 320K | 640K | 223K | 498K | 653K |
| Other Income/Expense | -130.58K | 37.99K | -1.15M | 1.53M | -1.37M | 1.9M | 41K | 16.88M | 5.31M | 2.35M |
| Pretax Income | -1.53M | -4.45M | -4.99M | -3.46M | -18.98M | -6.42M | -26.52M | -17.58M | -11.82M | -24.9M |
| Pretax Margin % | -4.22% | -31.06% | -3.42% | -2.37% | -158.14% | - | - | - | - | - |
| Income Tax | -380.16K | -766.89K | -95.09K | -1.07M | -4.58M | 198K | 133K | -1.52M | 83K | -381K |
| Effective Tax Rate % | 0.75% | 0.83% | 0.98% | 0.66% | 0.75% | 1.03% | 1.01% | 0.91% | 1.01% | 0.98% |
| Net Income | -1.15M | -3.68M | -4.9M | -2.29M | -14.31M | -6.6M | -26.65M | -16.06M | -11.9M | -24.52M |
| Net Margin % | -3.17% | -25.7% | -3.36% | -1.57% | -119.28% | - | - | - | - | - |
| Net Income Growth % | -15.7% | -2.21% | -0.33% | 0.53% | -5.24% | 0.54% | -3.04% | 0.4% | 0.26% | -1.06% |
| Net Income (Continuing) | -1.15M | -3.68M | -4.9M | -2.39M | -14.4M | -6.62M | -26.65M | -16.06M | -11.9M | -24.52M |
| Discontinued Operations | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 4.1M | 2.82M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00 | 0.00 | 0.00 | 0.00 | -189613.00 | -999999.00 | -999999.00 | -999999.00 | -6153.26 | -15.79 |
| EPS Growth % | 1% | - | - | - | - | -7.96% | -1.07% | 0.47% | 1% | 1% |
| EPS (Basic) | 0.00 | 0.00 | 0.00 | 0.00 | -189613.00 | -999999.00 | -999999.00 | -999999.00 | -6153.26 | -15.79 |
| Diluted Shares Outstanding | 0 | 0 | 0 | 0 | 75 | 4 | 8 | 11 | 3.32K | 1.61M |
| Basic Shares Outstanding | 0 | 0 | 0 | 0 | 75 | 4 | 8 | 11 | 3.32K | 1.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.94M | 4.37M | 1.31M | 2.21M | 3.34M | 1.72M | 21.4M | 4.97M | 1.97M | 22.34M |
| Cash & Short-Term Investments | 1.99M | 2.07M | 536.03K | 237.38K | 1.52M | 298K | 19.91M | 2.03M | 166K | 19.53M |
| Cash Only | 1.99M | 2.07M | 536.03K | 237.38K | 1.52M | 298K | 19.55M | 2.03M | 166K | 19.53M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 350K | 0 | 0 | 0 |
| Accounts Receivable | 92.87K | 2.31K | 407.74K | 0 | 1.66M | 1.12M | 1.34M | 871K | 946K | 2.23M |
| Days Sales Outstanding | 93.57 | 5.87 | 102 | - | 5.04K | - | - | - | - | - |
| Inventory | 2 | 34.69K | 168.9K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | 27.76 | - | - | - | - | - | - | - |
| Other Current Assets | 607.23K | 1.51M | 193.07K | 1.65M | 0 | 119K | 0 | 1.34M | 78K | 72K |
| Total Non-Current Assets | 2.51M | 2.17M | 786.96K | 36.38M | 28.26M | 31.69M | 28.23M | 9.58M | 9.89M | 309K |
| Property, Plant & Equipment | 0 | 68.51K | 21.76K | 55.7K | 437K | 352K | 94K | 27K | 20K | 309K |
| Fixed Asset Turnover | - | 2.09x | 67.06x | 26.22x | 0.27x | - | - | - | - | - |
| Goodwill | 2.31M | 1.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 200.32K | 158.87K | 0 | 36.33M | 27.69M | 30.49M | 28.14M | 9.55M | 9.87M | 0 |
| Long-Term Investments | 0 | 0 | 765.2K | 0 | 137K | 845K | 350K | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 28.33K | 0 | 0 | 0 | 0 | -350K | 0 | 0 | 0 |
| Total Assets | 5.45M | 6.54M | 2.09M | 38.59M | 31.61M | 33.4M | 49.63M | 14.54M | 11.86M | 22.65M |
| Asset Turnover | 0.07x | 0.02x | 0.70x | 0.04x | 0.00x | - | - | - | - | - |
| Asset Growth % | 57.41% | 0.2% | -0.68% | 17.44% | -0.18% | 0.06% | 0.49% | -0.71% | -0.18% | 0.91% |
| Total Current Liabilities | 518.15K | 1.34M | 1.7M | 5.43M | 4.72M | 5.53M | 20.72M | 11.22M | 14.17M | 10.84M |
| Accounts Payable | 0 | 1.27M | 472.37K | 1.94M | 2.18M | 0 | 698K | 6.25M | 8.42M | 4.18M |
| Days Payables Outstanding | - | - | 77.65 | 139.53 | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 2.9M | 536K | 1.52M | 0 | 2.64M | 1.3M | 1.35M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 501.68K | 25.25K | 1.23M | 592.14K | 0 | 3.64M | 11.27M | 374K | 3.99M | 1K |
| Current Ratio | 5.68x | 3.27x | 0.77x | 0.41x | 0.71x | 0.31x | 1.03x | 0.44x | 0.14x | 2.06x |
| Quick Ratio | 5.68x | 3.24x | 0.67x | 0.41x | 0.71x | 0.31x | 1.03x | 0.44x | 0.14x | 2.06x |
| Cash Conversion Cycle | - | - | 52.12 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 5.25M | 5.99M | 3.43M | 10.13M | 1.43M | 446K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 880K | 979K | 1.08M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 341K | 267K | 9K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.85M | 2.13M | 1.96M | 349K | 446K | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 5.25M | 3.79M | 149K | 7.18M | 0 | 0 | 0 |
| Total Liabilities | 518.15K | 1.34M | 1.7M | 10.69M | 10.7M | 8.96M | 30.85M | 12.65M | 14.61M | 10.84M |
| Total Debt | 0 | 0 | 0 | 2.9M | 963K | 2.67M | 1.09M | 3.73M | 1.3M | 1.35M |
| Net Debt | -1.99M | -2.07M | -536.03K | 2.66M | -561K | 2.37M | -18.47M | 1.71M | 1.13M | -18.18M |
| Debt / Equity | - | - | - | 0.10x | 0.05x | 0.11x | 0.06x | 1.98x | - | 0.11x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -35.45x | -102.70x | -1589.87x | -21.36x | -5.32x | -26.00x | -41.49x | -154.54x | -34.40x | -41.72x |
| Total Equity | 4.93M | 5.2M | 394.04K | 27.9M | 20.9M | 24.44M | 18.78M | 1.89M | -2.75M | 11.81M |
| Equity Growth % | 61.54% | 0.05% | -0.92% | 69.82% | -0.25% | 0.17% | -0.23% | -0.9% | -2.46% | 5.29% |
| Book Value per Share | - | - | - | - | 276916.69 | 999999.00 | 999999.00 | 166640.23 | -829.36 | 7.35 |
| Total Shareholders' Equity | 4.93M | 5.2M | 394.04K | 23.81M | 18.09M | 24.44M | 18.78M | 1.89M | -2.75M | 11.81M |
| Common Stock | 120K | 154.81K | 195.81K | 386.07K | 924K | 426K | 1K | 0 | 0 | 1K |
| Retained Earnings | -669.07K | 0 | -7.08M | -9.37M | -32.37M | -39.84M | -66.49M | -82.55M | -94.45M | -118.97M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -4.3M | -12.57K | 18.57K | -1.09M | 1.38M | -600K | -721K | -411K | -354K |
| Minority Interest | 0 | 0 | 0 | 4.1M | 2.82M | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.03M | -3.98M | -1.34M | -4.24M | -10.11M | -7.25M | -15.05M | -16.82M | -12.74M | -17.35M |
| Operating CF Margin % | -5.6% | -27.76% | -0.92% | -2.9% | -84.28% | - | - | - | - | - |
| Operating CF Growth % | - | -0.96% | 0.66% | -2.15% | -1.39% | 0.28% | -1.08% | -0.12% | 0.24% | -0.36% |
| Net Income | -1.15M | -3.68M | -4.9M | -2.29M | -14.4M | -5.07M | -26.65M | -16.06M | -11.9M | -24.52M |
| Depreciation & Amortization | 265.22K | 278.21K | 8.7K | 32.53K | 51K | 46K | 106K | 60K | 37K | 9K |
| Stock-Based Compensation | 0 | 0 | 2.33M | 214.06K | 333K | 616K | 6.37M | 1.75M | -71K | 71K |
| Deferred Taxes | 0 | 0 | 0 | 0 | -3.76M | -1.29M | 20K | -1.61M | 97K | -446K |
| Other Non-Cash Items | -424.83K | -599.35K | 1.05M | -2.47M | 5.6M | -2M | -466K | -631K | -4.26M | 7.47M |
| Working Capital Changes | -723.36K | 25.91K | 164.71K | 278.19K | 2.06M | 445K | 5.57M | -328K | 3.35M | 63K |
| Change in Receivables | -891.5K | -1.02M | 5K | 127.82K | -95K | 95K | 0 | 0 | -26K | 45K |
| Change in Inventory | 0 | 0 | -62.05K | 160.81K | 1.97M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 237K | -62K | -1.31M | 6.21M | 2.17M | -4.11M |
| Cash from Investing | 1.67M | -178.74K | -127.96K | 1.51M | 229K | -3K | 1M | 791K | 0 | -298K |
| Capital Expenditures | 0 | -77.84K | 0 | -5.68K | -8K | -3K | 0 | -18K | 0 | -298K |
| CapEx % of Revenue | - | 0.54% | - | 0% | 0.07% | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -259.33K | -100.9K | -127.96K | 1.63M | 0 | 0 | 1M | 809K | 0 | 0 |
| Cash from Financing | 3.77M | 4.31M | 1.16M | 2.42M | 11.2M | 6.03M | 33.82M | -1.31M | 10.99M | 36.79M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 3.77M | 4.31M | 1.16M | 2.42M | -1.48M | 0 | 725K | -800K | 2.24M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -2.03M | -4.06M | -1.34M | -4.24M | -10.12M | -7.25M | -15.05M | -16.84M | -12.74M | -17.65M |
| FCF Margin % | -5.6% | -28.31% | -0.92% | -2.91% | -84.34% | - | - | - | - | - |
| FCF Growth % | - | -1% | 0.67% | -2.16% | -1.38% | 0.28% | -1.07% | -0.12% | 0.24% | -0.38% |
| FCF per Share | - | - | - | - | -134079.98 | -999999.00 | -999999.00 | -999999.00 | -3842.33 | -10.98 |
| FCF Conversion (FCF/Net Income) | 1.77x | 1.08x | 0.27x | 1.85x | 0.71x | 1.10x | 0.56x | 1.05x | 1.07x | 0.71x |
| Interest Paid | 0 | 0 | 27.4K | 366.89K | 47K | 0 | 262K | 85K | 34K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 22K | 0 | 118K | 12K | 6K | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -45.78% | -72.69% | -175.1% | -16.2% | -58.65% | -29.12% | -123.3% | -155.34% | - | -541.17% |
| Return on Invested Capital (ROIC) | -69.25% | -110.87% | -193.07% | -24.57% | -51.89% | -26.47% | -146.86% | -1321.77% | -1298.31% | - |
| Gross Margin | 100% | 100% | -52.19% | -247.87% | 100% | - | - | - | - | - |
| Net Margin | -316.59% | -2570.36% | -335.69% | -156.97% | -11927.5% | - | - | - | - | - |
| Debt / Equity | - | - | - | 0.10x | 0.05x | 0.11x | 0.06x | 1.98x | - | 0.11x |
| Interest Coverage | -35.45x | -102.70x | -1589.87x | -21.36x | -5.32x | -26.00x | -41.49x | -154.54x | -34.40x | -41.72x |
| FCF Conversion | 1.77x | 1.08x | 0.27x | 1.85x | 0.71x | 1.10x | 0.56x | 1.05x | 1.07x | 0.71x |
| Revenue Growth | 3532.23% | -60.45% | 918.31% | 0.09% | -91.78% | -100% | - | - | - | - |
Allarity Therapeutics, Inc. (ALLR) grew revenue by 0.0% over the past year. Growth has been modest.
Allarity Therapeutics, Inc. (ALLR) reported a net loss of $15.3M for fiscal year 2024.
Allarity Therapeutics, Inc. (ALLR) has a return on equity (ROE) of -541.2%. Negative ROE indicates the company is unprofitable.
Allarity Therapeutics, Inc. (ALLR) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.